Form 8-K TherapeuticsMD, Inc. For: Feb 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Noble Trims PT on TherapeuticsMD (TXMD) to $17.50 Following Q4 Results; Affirms at 'Buy'
February 26, 2016 12:09 PM ESTNoble Financial affirms TherapeuticsMD (NYSE: TXMD) with a Buy rating, but trimmed its price target from $18 down to $17.50 following the company's Q4 report issued... More
